FDA expands Abilify use to schizophrenic teens

11/6/2007 | Wall Street Journal (free content), The · Yahoo!

The FDA has granted expanded approval to Bristol-Myers Squibb's antipsychotic drug Abilify for treatment of schizophrenic adolescents aged 13 to 17. The decision follows a six-week, 13-country study that showed the drug performed significantly better than placebo.

View Full Article in:

Wall Street Journal (free content), The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID